Why the study?
Do selective cyclooxygenase-2 inhibitors increase cardiovascular risk compared to conventional nonsteroidal anti-inflammatory drugs in patients with inflammatory disorders?
Do selective cyclooxygenase-2 inhibitors increase cardiovascular risk compared to conventional nonsteroidal anti-inflammatory drugs in patients with inflammatory disorders?
The cardiovascular safety profile of selective COX-2 inhibitors remains uncertain, necessitating dedicated randomized trials to definitively assess their cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Prescribers should exercise caution with COX-2 inhibitors; leaves open definitive CV risk assessment by dedicated RCTs.
Krum et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: